Similar articles

• Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study.

  Ehrt U, Broich K, Larsen JP, Ballard C, Aarsland D. Ehrt U, et al. J Neurol Neurosurg Psychiatry. 2010 Feb;81(2):160-5. doi: 10.1136/jnnp.2009.186239. Epub 2009 Sep 21. J Neurol Neurosurg Psychiatry. 2010. PMID: 19770163
• [Cognitive dysfunction in patients with Parkinson's disease].

  Zakharov VV, Iakhno NN. Zakharov VV, et al. Zh Nevrol Psikhiatr Im S S Korsakova. 2005;105(1):13-9. Zh Nevrol Psikhiatr Im S S Korsakova. 2005. PMID: 15704477 Russian.
• Acute and long-term administration of anticholinergics in Parkinson's disease: specific effects on the subcortico-frontal syndrome.

  Bédard MA, Pillon B, Dubois B, Duchesne N, Masson H, Agid Y. Bédard MA, et al. Brain Cogn. 1999 Jul;40(2):289-313. doi: 10.1006/brcg.1999.1083. Brain Cogn. 1999. PMID: 10413563 Clinical Trial.
• Anticholinergic therapies in the treatment of Parkinson's disease.

  [No authors listed] [No authors listed] Mov Disord. 2002;17 Suppl 4:S7-12. doi: 10.1002/mds.5556. Mov Disord. 2002. PMID: 12211135 Review. No abstract available.
• Drugs for Parkinson's disease.

  [No authors listed] [No authors listed] Treat Guidel Med Lett. 2011 Jan;9(101):1-6; quiz 2 p following 6. Treat Guidel Med Lett. 2011. PMID: 21304446 Review. No abstract available.